Our Company
Our story
Our vision and strategy
Fibrotic lung diseases
CEO statement
Board of Directors
Management
Scientific Advisers
Contact
Work with us
Our focus areas
Rare lung diseases
Role of the renin-angiotensin system
Role of the AT2 receptor
Our programs
Pipeline
Investors
Listing prospectus
Overview
Press releases
The share
Share monitor
Largest shareholders
Share issues
Share capital development
Analyst coverage
Financial reports
Financial calendar
Events & Presentations
Corporate governance
General meeting
Nomination committeé
Board of Directors
Audit Committee
Remuneration Committee
Scientific committee
Management
Remuneration and incentives
Auditors
Scientific Advisers
Articles of association
Image bank
Subscribe for press releases
Investor Relations contact
Investerare (SE)
Listningsprospekt
Översikt
Pressmeddelanden
Aktien
Aktiekursgraf
Största aktieägare
Aktiekapitalets utveckling
Emissioner
Analytiker
Finansiella rapporter
Finansiell kalender
Events & Presentationer
Bolagsstyrning
Bolagsstämma
Valberedning
Styrelsen
Revisionsutskott
Ersättningsutskott
Vetenskapligt utskott
Ledning
Arvoden och ersättningar
Revisorer
Vetenskapligt råd
Bolagsordning
Bildbank
Prenumerera på nyheter
Investerarkontakt
Patients and families
Disease background
Patient story
Resources and patient organizations
Working with patient groups
Access policy
Our commitment
Our Company
Our story
Our vision and strategy
Fibrotic lung diseases
CEO statement
Board of Directors
Management
Scientific Advisers
Contact
Work with us
Our focus areas
Rare lung diseases
Role of the renin-angiotensin system
Role of the AT2 receptor
Our programs
Pipeline
Investors
Investerare (SE)
Patients and families
Disease background
Patient story
Resources and patient organizations
Working with patient groups
Access policy
Our commitment
News
Home
/
Investors
/
Financial calendar
Overview
Press releases
The share
Share monitor
Largest shareholders
Share issues
Share capital development
Analyst coverage
Listing prospectus
Financial reports
Financial calendar
Events & Presentations
Corporate governance
Corporate governance reports
General meeting
Nomination committeé
Board of Directors
Audit Committee
Remuneration Committee
Scientific committee
Management
Remuneration and incentives
Auditors
Scientific Advisers
Articles of association
Image bank
Subscribe for press releases
Investor Relations contact
Financial calendar
Interim report Q3, 2021
4 November, 2021
Year-end report 2021
25 February, 2022